Rossi Sabrina, Finocchiaro Giovanna, Marchetti Silvia, Toschi Luca, Santoro Armando
Department of Oncology & Hematology, Humanitas Clinical & Research Center, Rozzano (MI), Italy.
Immunotherapy. 2018 Apr;10(5):403-410. doi: 10.2217/imt-2017-0151.
Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.
尽管已做出诸多努力，但脑转移瘤（BM）仍是非小细胞肺癌（NSCLC）患者治疗中的关键问题。迄今为止，放射治疗仍被视为金标准治疗方法；另一方面，全身化疗药物对BM并非经常是有效的治疗手段，而在致癌基因成瘾性疾病中，靶向药物对BM也显示出良好的活性。抗程序性死亡蛋白1/程序性死亡配体1药物是NSCLC以及多种肿瘤类型的一种新的有效治疗策略，但其对BM患者的疗效仍不明确，主要是由于临床试验中采用了严格的选择标准。本文旨在探讨检查点抑制剂对NSCLC脑转移患者的潜在活性。
